Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Fosun Kairos, has had its drug registration application for Brexucabtagene Autoleucel Injection accepted by the National Medical Products Administration. This product, a CD19-targeted CAR-T cell therapy, is intended for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The development of this therapy is based on technology transferred from Kite Pharma, a subsidiary of Gilead Sciences. The acceptance of this application marks a significant step for Fosun Pharma in expanding its portfolio of innovative treatments and strengthening its position in the biopharmaceutical industry.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a leading pharmaceutical company based in China, specializing in the development and production of therapeutic biological products. The company focuses on innovative healthcare solutions, including CAR-T cell therapies, and operates in both domestic and international markets.
Average Trading Volume: 11,475,661
Technical Sentiment Signal: Buy
Current Market Cap: HK$86.28B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.